Therapeutic effects of stronger neo-minophagen C at different doses on chronic hepatitis and liver cirrhosis
Therapeutic effects of stronger neo-minophagen C at different doses on chronic hepatitis and liver cirrhosis
复制标题
DOI：
10.1016/s1386-6346(00)00079-6
复制
发表时间：
2001-01-01
影响因子：
4.2
通讯作者：
Suzuki, H
中科院分区：
文献类型：
--
作者：
Iino, S;Tango, T;Suzuki, H
更强的新辅酶C(SNMC)是一种甘草酸(GL)制剂，在日本已被广泛用于慢性肝炎的治疗，并取得了相当大的成功。本研究的目的是阐明大剂量100ml/d对标准剂量(40ml/d)治疗2周效果不佳的患者的疗效。随机将178例入选病例中的100例(56.2%)分为两组，一组每日服用100ml/d，疗程3周；另一组每日每日服用40ml，疗程3周。根据治疗后3周ALT水平(分别为正常上限的1.2倍和1.2-1.5倍)，将患者分为“显著改善”和“改善”两组。除了那些辍学或不符合分析条件的人外，44例和46例进行了分析。A组44例中有23例(52.3%)评分为“好转”，而B组46例中仅有12例(26.1%)评分为“进步”或以上。与B组相比，A组有显著改善(P=0.017)，从而证明每天服用100ml的SNMC比只服用40ml的疗效更好。(C)2000爱思唯尔爱尔兰科学有限公司。保留所有权利。
Stronger neo-minophagen C (SNMC), a glycyrrhizin (GL) preparation, has been extensively used with considerable success in Japan for the treatment of chronic hepatitis. The aim of the present study was to elucidate the efficacy of administering massive doses of 100 ml/day to patients in whom standard administration (40 ml/day) for 2 weeks did not show sufficient improvement. A comparative study was conducted by dividing at random 100 cases (56.2%), out of a total of 178 enrolled, into two groups, one for the administration of 100 ml/day for 3 weeks (group A) and the other for administration of 40 ml/day for 3 weeks (group B) Cases were rated 'markedly improved' or 'improved' according to their ALT levels (defined respectively as < 1.2 limes and 1.2-1.5 times the normal upper level 3 weeks after treatment). Except those who dropped out or were otherwise not eligible for analysis, 44 and 46 cases were analyzed. In group Al 23 of 44 cases (52.3%) were rated 'improved' ol better whereas only 12 of 46 (26.1%) in group B were 'improved' or better. Group A showed significant improvement compared to group B (P = 0.017), thus documenting the greater efficacy of administering SNMC at 100 ml/day compared to only 40 ml/day. (C) 2000 Elsevier Science Ireland Ltd. All rights reserved.